Litoxetine
 | |
| Clinical data | |
|---|---|
| Other names | SL 81-0385; IXA-001 |
| ATC code |
|
| Identifiers | |
| |
JSmol) | |
| |
Litoxetine (developmental code names SL 81-0385, IXA-001) is an
5-HT3 receptor antagonist (Ki = 315 nM).[3][4] It has antiemetic activity, and unlike the selective serotonin reuptake inhibitors (SSRIs), appears to have a negligible incidence of nausea and vomiting.[5] The drug is structurally related to indalpine.[4] Development of litoxetine for depression was apparently ceased in the late 1990s.[1] However, as of March 2017, development of litoxetine has been reinitiated and the drug is now in the phase II stage for the treatment of urinary incontinence.[1]
References
- ^ a b c "Litoxetine - IXALTIS". AdisInsight. Springer Nature Switzerland AG. Retrieved 2018-08-25.
- PMID 8562293.
- ISBN 978-1-84973-494-3.
- ^ ISBN 978-3-0348-8391-7.
- PMID 8385615.
External links
- "Litoxetine". Drug Information Portal. U.S. National Library of Medicine.
